Pegsunercept

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 108.35.217.152 (talk) at 21:50, 18 February 2019 (→‎References). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pegsunercept
Clinical data
Routes of
administration
subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • investigational
Pharmacokinetic data
BioavailabilityN/A
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC502H758N154O165S16
Molar mass12,103 g/mol (protein part) g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]

References

  1. ^ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
  3. ^ a b Furst, D.; Fleischmann, R.; Kopp, E.; Schiff, M.; Edwards C, 3.; Solinger, A.; Macri, M.; 990136 Study, G. (2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–2310. PMID 16331754. {{cite journal}}: |first5= has numeric name (help)CS1 maint: numeric names: authors list (link)